MedTrace Logo

Study to Investigate the Efficacy of Symbicort® SMART.

NCT00839800 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2091

Last updated 2012-11-30

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to compare the efficacy of Symbicort SMART (Symbicort Turbuhaler 160/4.5μg, one inhalation twice daily plus as needed) with Symbicort Turbuhaler 160/4.5μg, one inhalation twice daily plus terbutaline Turbuhaler 0.4 mg as needed, as asthma therapy

Conditions

Interventions

DRUG

Symbicort Turbuhaler

160/4.5 µg

DRUG

Terbutaline Turbuhaler

0.4 mg

Sponsors & Collaborators

Principal Investigators

  • Tomas Andersson, MD · AstraZeneca R&D Lund

  • Tito Atienza, M.D. · Mary Mediatrix Medical Center, Lipa City, Philippines

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2011-02-28
Completion
2011-02-28

Countries

  • Argentina
  • Brazil
  • China
  • Costa Rica
  • Hungary
  • India
  • Japan
  • Malaysia
  • Peru
  • Philippines
  • South Korea
  • Thailand

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00839800 on ClinicalTrials.gov